Tenon Medical (TNON) POS AM 10 May 24 Prospectus update (post-effective amendment) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2023
Document Information Line Items
Entity Registrant Name	TENON MEDICAL, inc.
Document Type	POS AM
Amendment Flag	true
Amendment Description	This Post-Effective Amendment No. 1 on Form S-1 to the Registration Statement on Form S-1 (Registration No. 333-272488) (the “Original Registration Statement”), which was declared effective by the Commission on June 13, 2023, is being filed to serve as a Section 10(a)(3) update to the Original Registration Statement and to make certain other updates to the prospectus that forms a part of this Post-Effective Amendment. Pursuant to Rule 416 under the Securities Act, there are also being registered such securities that may be issued because of events such as recapitalizations, stock dividends, stock splits and reverse stock splits, and similar transactions. All applicable registration fees were paid at the time of the filing of the Original Registration Statement.
Entity Central Index Key	0001560293
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Incorporation, State or Country Code	DE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,428	$ 2,129
Short-term investments		6,441
Accounts receivable	518	228
Inventory, net	554	415
Prepaid expenses	389	134
Total current assets	3,889	9,347
Fixed assets, net	961	793
Deposits	51	51
Operating lease right-of-use asset	646	873
Deferred offering costs	798	25
TOTAL ASSETS	6,345	11,089
Current liabilities:
Accounts payable	433	550
Accrued expenses	808	717
Current portion of accrued commissions	470	1,035
Current portion of operating lease liability	256	228
Convertible notes payable and accrued interest, net of debt discount of $77 and $0 at December 31, 2023 and 2022, respectively	1,173
Total current liabilities	3,140	2,530
Accrued commissions, net of current portion	1,999	1,624
Operating lease liability, net of current portion	428	683
Total liabilities	5,567	4,837
Commitments and contingencies (Notes 6 and 10)
Stockholders’ equity:
Common stock, $0.001 par value; 130,000,000 shares authorized at December 31, 2023 and 2022; 2,600,311 and 1,123,680 shares issued and outstanding at December 31, 2023 and 2022, respectively	3	1
Additional paid-in capital	55,894	45,843
Accumulated deficit	(55,073)	(39,492)
Accumulated other comprehensive loss	(46)	(100)
Total stockholders’ equity	778	6,252
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 6,345	$ 11,089

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Net of debt discount (in Dollars)	$ 77	$ 0
Common stock par or stated value per share (in Dollars per share)	$ 0.001	$ 0.001
Common stock shares authorized	130,000,000	130,000,000
Common stock shares outstanding	2,600,311	1,123,680
Common stock shares issued	2,600,311	1,123,680

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 2,928	$ 691
Cost of sales	1,687	1,332
Gross Profit (Loss)	1,241	(641)
Operating Expenses
Research and development	3,163	2,828
Sales and marketing	6,778	7,833
General and administrative	7,027	7,423
Total Operating Expenses	16,968	18,084
Loss from Operations	(15,727)	(18,725)
Other Income (Expense)
Gain on investments	167	180
Interest expense	(21)	(354)
Other expense, net		(18)
Total Other Income (Expense), net	146	(192)
Net Loss	$ (15,581)	$ (18,917)
Net Loss Per Share of Common Stock
Basic (in Dollars per share)	$ (8.59)	$ (23.62)
Weighted-Average Shares of Common Stock Outstanding
Basic (in Shares)	1,814	801
Consolidated Statements of Comprehensive Loss:
Net loss	$ (15,581)	$ (18,917)
Unrealized loss on investments	16	(16)
Foreign currency translation adjustment	38	7
Total Comprehensive Loss	$ (15,527)	$ (18,926)

Consolidated Statements of Op_2

Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Diluted	$ (8.59)	$ (23.62)
Diluted	1,814	801

Consolidated Statements of Conv

Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) - USD ($) $ in Thousands	Series A Convertible Preferred Stock	Series B Convertible Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Balance at Dec. 31, 2021	$ 12,367	$ 1,272		$ 114	$ (20,575)	$ (91)	$ (20,552)
Balance (in Shares) at Dec. 31, 2021	2,550,763	491,222	98,995
Stock-based compensation expense				2,897			2,897
Issuance of common stock and warrants, net of issuance costs				13,765			13,765
Issuance of common stock and warrants, net of issuance costs (in Shares)			320,000
Common stock issued upon conversion of Series A preferred stock	$ (12,367)			12,367			12,367
Common stock issued upon conversion of Series A preferred stock (in Shares)	(2,550,763)		244,773
Common stock issued upon conversion of Series B preferred stock		$ (1,272)		1,272			1,272
Common stock issued upon conversion of Series B preferred stock (in Shares)		(491,222)	24,561
Common stock issued upon conversion of debt			$ 1	13,867			13,868
Common stock issued upon conversion of debt (in Shares)			395,542
Common stock issued for services				1,561			1,561
Common stock issued for services (in Shares)			39,809
Other comprehensive income (loss)						(9)	(9)
Net loss					(18,917)		(18,917)
Balance at Dec. 31, 2022			$ 1	45,843	(39,492)	(100)	6,252
Balance (in Shares) at Dec. 31, 2022			1,123,680
Stock-based compensation expense				4,145			4,145
Release of restricted stock units
Release of restricted stock units (in Shares)			61,200
Issuance of common stock and warrants, net of issuance costs			$ 1	4,807			4,808
Issuance of common stock and warrants, net of issuance costs (in Shares)			1,000,000
Issuance of common stock, net of issuance costs			$ 1	494			495
Issuance of common stock, net of issuance costs (in Shares)			232,100
Common stock issued for services				289			289
Common stock issued for services (in Shares)			98,909
Issuance of common stock upon exercise of warrants				258			258
Issuance of common stock upon exercise of warrants (in Shares)			82,000
Warrants issued in connection with convertible debt				58			58
Shares issued for reverse stock split
Shares issued for reverse stock split (in Shares)			2,422
Other comprehensive income (loss)						54	54
Net loss					(15,581)		(15,581)
Balance at Dec. 31, 2023			$ 3	$ 55,894	$ (55,073)	$ (46)	$ 778
Balance (in Shares) at Dec. 31, 2023			2,600,311

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash Flows from Operating Activities
Net loss	$ (15,581)	$ (18,917)
Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized loss on investments		(16)
Non-cash interest expense		362
Stock-based compensation expense	4,145	2,897
Common stock issued for services		1,561
Depreciation and amortization	199	78
Loss on write-off of fixed assets		77
Amortization of operating right-of-use asset	227	211
Increase (decrease) in cash resulting from changes in:
Accounts receivable	(290)	(152)
Inventory	(139)	(227)
Prepaid expenses and other assets	(301)	(57)
Accounts payable	(117)	72
Accrued expenses	(99)	2,288
Operating lease liability	(227)	(202)
Net cash used in operating activities	(12,183)	(12,025)
Cash Flows from Investing Activities
Sales of short-term investments	6,996	8,079
Purchases of short-term investments	(493)	(10,116)
Purchases of property and equipment	(361)	(847)
Net cash provided by (used in) investing activities	6,142	(2,884)
Cash Flows from Financing Activities
Proceeds from issuance of common stock and warrants, net of issuance costs	4,808	14,139
Proceeds from issuance of common stock, net of issuance costs	495
Proceeds from issuance of convertible notes payable	1,250
Proceeds from exercise of warrants	258
Deferred offering costs	(509)	(25)
Net cash provided by financing activities	6,302	14,114
Effect of foreign currency translation on cash flow	38	7
Net Increase (Decrease) in Cash and Cash Equivalents	299	(788)
Cash and Cash Equivalents at Beginning of Year	2,129	2,917
Cash and Cash Equivalents at End of Year	2,428	2,129
Cash at End of Year	2,428	480
Cash Equivalents at End of Year		1,649
Cash paid during the year for:
Interest
Income taxes
Non-cash investment and financing activities:
Common stock issued upon conversion of preferred stock		13,639
Common stock issued upon conversion of debt		$ 13,868

Organization and Business

Organization and Business	12 Months Ended
	Dec. 31, 2023
Organization and Business [Abstract]
Organization and Business	1. Organization and Business Nature of operations Tenon Medical, Inc. (the “Company”) was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. The Company is a medical device company that has developed The Catamaran™ SI Joint Fusion System (“the Catamaran System”) that offers a novel, less invasive approach to the sacroiliac joint (the “SI Joint”) using a single, robust, titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. The Company received U.S. Food and Drug Administration (“FDA”) clearance in 2018 for The Catamaran System and is currently focused on the U.S. market. Since the national launch of the Catamaran System in October 2022, the Company is focused on three commercial opportunities: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants and 3) SI Joint fusion adjunct to a spine fusion construct. Basis of consolidation The condensed financial statements of the Company include the accounts of the Company and its wholly-owned subsidiary, Tenon Technology AG (“TTAG”), a Swiss company. All intercompany balances and transactions have been eliminated in consolidation. The financial statements of TTAG are prepared for the same reporting period as the parent, using consistent accounting policies in all material respects.

Summary of Significant Accounti

Summary of Significant Accounting Principles	12 Months Ended
	Dec. 31, 2023
Summary of Significant Accounting Principles [Abstract]
Summary of Significant Accounting Principles	2. Summary of Significant Accounting Principles Basis of presentation The accompanying consolidated financial statements have been prepared on the accrual basis in accordance with generally accepted accounting principles as promulgated in the United States of America (“U.S. GAAP”). Going concern uncertainty and liquidity requirements The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. There is substantial doubt about the Company’s ability to continue as a going concern for one year after the date that these financial statements are issued. Since inception, the Company has incurred losses and negative cash flows from operations. Management expects to incur additional operating losses and negative cash flows from operations in the foreseeable future as the Company continues its product development programs and the commercialization of The Catamaran System. Based on the Company’s expected level of revenues and expenditures, the Company believes that its existing cash and cash equivalents as of December 31, 2023 will not provide sufficient funds to enable it to meet its obligations for a period of at least twelve months from the date of the filing of these consolidated financial statements. The Company plans to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations (see Note 13). The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, obsolescence of inventory, the fair value of accrued commissions and stock-based compensation. Reverse Stock Splits On April 6, 2022, the Company effected a 1-for-2 reverse stock split (the “2022 Reverse Stock Split”) by filing an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Delaware Secretary of State. The 2022 Reverse Stock Split combined every two shares of our common stock issued and outstanding immediately prior to effecting the 2022 Reverse Stock Split into one share of common stock. Similarly, shares of Series A and Series B Preferred Stock became convertible into common stock at a conversion rate of one-to-0.5, subject to adjustments for stock dividends, splits, combinations, and similar events. No fractional shares were issued in connection with the 2022 Reverse Stock Split. On November 2, 2023, the Company effected a 1-for-10 reverse stock split (the “2023 Reverse Stock Split”) by filing an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Delaware Secretary of State. The 2023 Reverse Stock Split combined every ten shares of our common stock issued and outstanding immediately prior to effecting the 2023 Reverse Stock Split into one share of common stock. No fractional shares were issued in connection with the 2023 Reverse Stock Split. All historical share and per share amounts reflected throughout this document have been adjusted to reflect the 2022 Reverse Stock Split and the 2023 Reverse Stock Split. The authorized number of shares and the par value per share of the Company’s common stock were not affected by the 2022 Reverse Stock Split or the 2023 Reverse Stock Split. Segments The Company operates in one business segment. Although the Company’s Swiss subsidiary is located in a different geographical area, management uses one measurement of profitability and does not segregate its business for internal reporting. Cash and cash equivalents The Company considers all highly liquid investments with maturities of 90 days or less at the date of purchase to be cash equivalents. Investments The Company classifies its investments in marketable securities as available-for-sale and records them at fair value in its consolidated balance sheets. The net unrealized gains and losses are recorded as a separate component of stockholders’ equity. Realized gains and losses are recorded in the consolidated statements of operations and comprehensive loss. The Company determines any realized gains or losses on the sale of marketable debt securities on a specific identification method and records such gains and losses as a component of other income (expense) net. Accounts receivable and allowance for doubtful accounts Accounts receivable are derived from products delivered to customers and are stated at their net realizable value. The Company records an allowance for estimated uncollectible accounts in an amount approximating anticipated losses. Individual uncollectible accounts are written off against the allowance when collection of the individual accounts appears doubtful. In determining the amount of the allowance, the Company considers its historical level of credit losses. The Company also makes judgments about the creditworthiness of significant customers based on ongoing credit evaluations, and the Company assesses current economic trends that might impact the level of credit losses in the future. Historically, the Company has had no significant write-offs of accounts receivable. However, since the Company cannot reliably predict future changes in the financial stability of its customers, it cannot guarantee that its allowances will continue to be adequate. If actual credit losses are significantly greater than the allowance, the Company would increase its general and administrative expenses and increase its reported net losses. As of December 31, 2023 and 2022, the Company’s allowance for expected credit losses was $0. Inventory Inventory is stated at lower of cost or net realizable value. The Company establishes the inventory basis by determining the cost based on standard costs approximating the purchase costs on a first-in, first-out basis. The excess and obsolete inventory is estimated based on future demand and market conditions. Inventory write-downs are charged to cost of goods sold. As of December 31, 2023 and 2022, inventory consisted of finished goods and raw materials. Deferred offering costs Deferred offering costs, which consist of direct incremental legal, consulting, banking, and accounting fees relating to the Company’s future offerings, are capitalized, and are offset against proceeds received upon the effectiveness of the offering. In the event an anticipated offering is terminated, deferred offering costs will be expensed. Fixed assets, net Fixed assets are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Equipment, computers, software, and furniture and fixtures are depreciated over periods ranging from three to seven years, and leasehold improvements over the shorter of the lease term or the life of the asset. Construction in progress pertains to the cost of individual components of a custom instrument set used for surgical placement of the Company’s products that have not yet been placed into service. The cost of maintenance and repairs is charged to expense as incurred; significant renewals and betterments are capitalized. Deductions are made for retirements resulting from renewals or betterments. Leases The Company leases its headquarters in Los Gatos, California. At the inception of a contract, the Company assesses whether that contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefit from the use of the asset throughout the term, and (3) whether the Company has the right to direct the use of the asset. At inception of a lease, the Company allocates the consideration in the contract to each lease and non-lease component based on the component’s relative stand-alone price to determine the lease payments. Lease and non-lease components are accounted for separately. Leases are classified as either finance leases or operating leases based on criteria in FASB ASC 842, “Leases”. The Company’s facility lease is classified as an operating lease. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease’s commencement date based on the present value of lease payments over the lease term. When a lease did not provide an implicit rate, the Company used its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The Company has elected not to recognize ROU assets and lease liabilities for short-term operating leases that have a term of 12 months or less. Lease expense for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses in the consolidated statements of operations and comprehensive loss. Long-lived assets The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist that warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management’s estimate of the asset’s ability to generate positive income from operations and positive undiscounted cash flow in future periods as well as the strategic significance of the assets to the Company’s business objectives. Fair value measurements In accordance with Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, fair value is the price that would be received from selling an asset or paid to transfer a liability (i.e., the exit price) in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels based on the inputs as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reported date. Level 2 – Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reported date. The nature of these financial instruments includes cash instruments for which quoted prices are available but are traded less frequently, derivative instruments whose fair values have been derived using a model where inputs to the model are directly observable in the market and instruments that are fair valued using other financial instruments, the parameters of which can be directly observed. Level 3 – Instruments that have little to no pricing observability as of the measurement date. These financial instruments are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment or estimation. The degree of judgment exercised by the Company in determining fair value is greatest for assets categorized in Level 3. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety is determined by the lowest level input that is significant to the fair value measurement. Income taxes Income taxes are recorded in accordance with Financial Accounting Standards Board (“FASB”) ASC Topic 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. Under this method, the Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect when the differences are expected to reverse. Valuation allowances are provided when necessary to reduce net deferred tax assets to the amount that is more likely than not to be realized. Based on the available evidence, the Company is unable, at this time, to support the determination that it is more likely than not that its deferred tax assets will be utilized in the future. Accordingly, the Company recorded a full valuation allowance as of December 31, 2023 and 2022. The Company intends to maintain valuation allowances until sufficient evidence exists to support its reversal. Current income taxes are based upon the year’s income taxable for federal, state, and foreign tax reporting purposes. Deferred income taxes are provided for certain income and expenses, which are recognized in different periods for tax and financial reporting purposes. The Company’s policy is not to record deferred income taxes on the undistributed earnings of foreign subsidiaries that are indefinitely reinvested in foreign operations. Revenue recognition The Company’s revenue is derived from the sale of its products to medical groups and hospitals in the United States. Revenue is recognized when control is transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for the goods or services, using the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied. The Company generates revenue from the sale of products to hospitals or medical facilities where its products are delivered in advance of a procedure. The performance obligation is the delivery of the products along with the completion of the surgery and therefore, revenue is recognized upon delivery to the customers and completion of the surgery, net of rebates and price discounts. The Company accounts for rebates and price discounts as a reduction to revenue, calculated based on the terms agreed to with the customer. Historically, there have been no significant rebates or price discounts. Sales prices are specified prior to the transfer of control to the customer, via either the customer contract, agreed price list, purchase order, or written communication with the customer. Prior to October 2022, the Company had an agreement in place with a national distributor, which included standard terms that did not allow for payment contingent on resale of the product, obtaining financing, or other terms that could impact the distributor’s payment obligation. The Company billed and collected directly with the end-user customers and recognized revenue based on the gross sales price. For direct sales to end-user customers, the Company’s standard payment terms are generally net 30 days. The Company offers its standard warranty to all customers and does not sell any warranties on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and includes an offer to replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records them as a charge to cost of goods sold. Contract modifications generally do not occur during the performance of the Company’s contracts. Payments received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the consolidated balance sheets. As of December 31, 2023 and 2022, there were no remaining performance obligations that would give rise to deferred revenue. Sales commissions are recorded in sales and marketing expenses during the same period as the corresponding revenues. Research and development The Company engages in improving existing products and new product development efforts. Research and development expenses relating to these efforts are expensed as incurred. Stock-based compensation The Company accounts for all stock-based compensation awards using a fair-value method on the grant date and recognizes the fair value of each award as an expense over the requisite service period. The Company recognizes compensation costs related to stock-based awards granted to employees, directors, and consultants including stock options, based on the estimated fair value of the awards on the date of grant. We estimate the grant date fair value, and the resulting stock-based compensation, using the Black-Scholes option-pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Black-Scholes option-pricing model requires the use of subjective assumptions to determine the fair value of stock-based awards. These assumptions include: Expected Term Expected Volatility Risk-Free Interest Rate Expected Dividend The Company account for forfeitures as they occur. The Company’s board of directors intends all options granted to be exercisable at a price per share not less than the per share fair value of our common stock underlying those options on the date of grant. Prior to the Company’s initial public offering, the estimated fair value of its common stock was determined at each valuation date by a third-party independent valuation firm in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. These valuations took into account numerous factors, including developments at our company and market conditions. The May 21, 2021 valuation used a hybrid method which combines the Probability Weighted Expected Return Method (“PWERM”) with the OPM. The PWERM considers a set of discrete potential liquidity scenarios for the Company, the value common stock would receive in each scenario, and the time required and risk inherent in achieving those values. The May 21, 2021 valuation examined the following scenarios for the Company: (i) an IPO; (ii) remaining private and raising capital; and (iii) dissolution. Within the IPO scenario, 100% weighting was placed on the Market Approach for determining the enterprise value. The Market Approach assumes that businesses operating in the same industry will share similar characteristics, and therefore a comparison of the business to similar businesses whose financial information is publicly available may provide a reasonable basis to estimate a subject business’s value. The equity value in the IPO scenario was estimated considering guideline IPOs, the anticipated size of the Company’s offering, and forecasted cash and debt. The estimated common stock value as of the IPO was present valued using a discount rate of 22.4% based on Company’s WACC, less an adjustment of 2.0% to reflect the risk reduction of an IPO event. The August 31, 2021 valuation used a hybrid method which combines the Probability Weighted Expected Return Method (“PWERM”) with the OPM. The PWERM considers a set of discrete potential liquidity scenarios for the Company, the value common stock would receive in each scenario, and the time required and risk inherent in achieving those values. The August 31, 2021 valuation examined the following scenarios for the Company: (i) an IPO; (ii) remaining private and raising capital; and (iii) dissolution. Within the IPO scenario, 100% weighting was placed on the Market Approach for determining the enterprise value. The Market Approach assumes that businesses operating in the same industry will share similar characteristics, and therefore a comparison of the business to similar businesses whose financial information is publicly available may provide a reasonable basis to estimate a subject business’s value. The equity value in the IPO scenario was estimated considering guideline IPOs, the anticipated size of the Company’s offering, and forecasted cash and debt. The estimated common stock value as of the IPO was present valued using a discount rate of 32.0% based on Company’s WACC, less an adjustment of 5.0% to reflect the risk reduction of an IPO event. The October 28, 2021 valuation used a hybrid method which combines the Probability Weighted Expected Return Method (“PWERM”) with the OPM. The PWERM considers a set of discrete potential liquidity scenarios for the Company, the value common stock would receive in each scenario, and the time required and risk inherent in achieving those values. The October 28, 2021 valuation examined the following scenarios for the Company: (i) an IPO; (ii) remaining private and raising capital; and (iii) dissolution. Within the IPO scenario, 100% In determining the enterprise value within the remain private scenario, 100% weighting was applied to the DCF Method under the income approach, in the same manner as in the December 31, 2018, 2019, and 2020 valuations. The discount rate in this scenario was determined to be 22.4% based on Company’s WACC. Adjustments were made to the enterprise value for the Company’s cash and debt as of the valuation date to determine the equity value in this scenario. The OPM was used to allocate the equity value to our common stock. The equity volatility rate was determined to be 70.0% based on the volatility rate of certain comparable public companies. DLOMs of (i) 10.0% in the IPO scenario and (ii) 30.0% in the remaining private scenario were applied to the common stock. Following the closing of the initial public offering, the fair value of the Company’s common stock was determined based on the closing price of its common stock on the Nasdaq Capital Market. Foreign currency translation and other comprehensive income The functional currency of Tenon Technology AG is the Swiss franc. Accordingly, TTAG’s assets and liabilities are translated from their respective functional currency into U.S. Dollars at period-end rates, and TTAG’s revenue and expenses are translated at the weighted-average exchange rate for the period. Adjustments resulting from this translation process are classified as other comprehensive income or loss and shown as a separate component of equity. When intercompany foreign currency transactions between entities included in the consolidated financial statements are of a long-term investment nature (i.e., those for which settlement is not planned or anticipated in the foreseeable future) foreign currency translation adjustments resulting from those transactions are included in stockholders’ equity (deficit) as accumulated other comprehensive loss or income. When intercompany transactions are deemed to be of a short-term nature, translation adjustments are required to be included in the consolidated statements of operations. Net loss per share Basic net loss per share is based upon the weighted-average number of common shares outstanding. Diluted net loss per share is based on the assumption that all potential common stock equivalents (convertible preferred stock, stock options, and warrants) are converted or exercised. The calculation of diluted net loss per share excludes potential common stock equivalents if the effect is anti-dilutive. For the periods presented, the Company’s weighted-average common shares outstanding for basic and diluted are the same because the effect of the potential common stock equivalents is anti-dilutive. The Company had the following dilutive common stock equivalents as of December 31, 2023 and 2022 which were excluded from the calculation because their effect was anti-dilutive. December 31, December 31, Outstanding restricted stock units 76,916 131,858 Outstanding stock options 102,089 89,889 Outstanding warrants 1,927,600 9,600 Total 2,106,605 231,347 Adoption of New Accounting Pronouncements In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update 2016-13, “ Financial Instruments-Credit Losses Measurement of Credit Losses on Financial Instruments

Investments

Investments	12 Months Ended
	Dec. 31, 2023
Investments [Abstract]
Investments	3. Investments The following table sets forth by level, within the fair value hierarchy, the Company’s investments at fair value as of December 31, 2023 and 2022: Level 2 Corporate debt securities: December 31, 2023 $ — December 31, 2022 $ 6,441 Cost and fair value of available-for-sale investments as of December 31, 2023 and 2022 are as follows: Amortized Gross Gross Unrealized Losses Fair Corporate debt securities: December 31, 2023 $ — $ — $ — $ — December 31, 2022 $ 6,457 $ — $ (16 ) $ 6,441 All of the investments with gross unrealized losses have been in a continuous loss position for less than 12 months. During the years ended December 31, 2023 and 2022, the Company did not recognize any significant other-than-temporary impairment losses because the Company does not intend to sell the investments before recovery of their amortized cost bases. During the years ended December 31, 2023 and 2022, there were net gains of approximately $167 and $180, respectively, included in the Company’s net loss. Accrued interest as of December 31, 2023 and 2022 was approximately $8 and $13, respectively, and is included in prepaid expenses in the Company’s consolidated balance sheets.

Inventory, Net

Inventory, Net	12 Months Ended
	Dec. 31, 2023
Inventory [Abstract]
Inventory, net	4. Inventory, net Inventory, net of reserves, consisted of the following: December 31, December 31, Raw materials $ 22 $ 9 Finished goods 532 406 Inventory $ 554 $ 415

Fixed Assets, Net

Fixed Assets, Net	12 Months Ended
	Dec. 31, 2023
Fixed Assets, Net [Abstract]
Fixed Assets, net	5. Fixed Assets, net Fixed assets, net, consisted of the following: December 31, December 31, Construction in progress $ 602 $ 601 Catamaran tray sets 538 193 IT equipment 56 56 Leasehold improvements 15 — Lab equipment 14 14 Office furniture 9 9 Fixed assets, gross 1,234 873 Less: accumulated depreciation (273 ) (80 ) Fixed assets, net $ 961 $ 793 Construction in progress is made up of reusable components that will become Catamaran Tray Sets. Depreciation expense was approximately $193 and $78 for the years ended December 31, 2023 and 2022, respectively.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2023
Accrued Expenses [Abstract]
Accrued Expenses	6. Accrued Expenses Accrued expenses consisted of the following: December 31, December 31, Accrued compensation $ 334 $ 452 Other accrued expenses 474 265 Total accrued expenses $ 808 $ 717

Debt

Debt	12 Months Ended
	Dec. 31, 2023
Debt [Abstract]
Debt	7. Debt Convertible notes payable In November 2023, the Company entered into Securities Purchase Agreements with certain investors (the “Investors”), pursuant to which the Company sold to the Investors a total of $1,250,000 in secured notes (the “Convertible Notes”) and warrants to purchase 45,000 shares of the Company’s common stock at an exercise price equal to $1.94 per share. The Convertible Notes bear an interest rate of 10% per annum with a default rate of 12% per annum and have a maturity date of November 21, 2024. All principal and accrued interest is payable at maturity. At any time during the term of the Convertible Notes, the principal amount together with all accrued interest thereon (the “Prepayment Amount”) may be paid in full, but not in part, by the Company. The Prepayment Amount may be paid by the Company in cash or by the issuance to the Investors of shares of Series A Preferred Stock, if prior to such payment with Series A Preferred Stock (i) certain stockholder proposals described in the Convertible Notes are approved by the Company’s stockholders; and (ii) the Company has commitments from investors other than the Investors to purchase shares of Series A Preferred Stock with a stated value of at least $3,750,000. The Convertible Notes are secured by a first priority security interest in all of the assets of the Company. The warrants expire five years from the issuance date. The warrants contain a “cashless exercise” feature and contain anti-dilution rights on subsequent issuances of equity or equity equivalents. On February 20, 2024, the Investors agreed to a complete prepayment of the Company’s obligations under the Convertible Notes, including accrued interest, in exchange for 84,729 shares of Series A Preferred Stock and warrants to purchase 157,094 shares of our common stock at $1.2705 per share and the Convertible Notes were cancelled. See Note 13.

Leases

Leases	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Leases	8. Leases In June 2021, the Company entered into a facility lease agreement for its company headquarters in Los Gatos, California. This non-cancellable operating lease expires in June 2026. Operating lease costs for the facility lease were $292 and $292 for the years ended December 31, 2023 and 2022, respectively. Supplemental balance sheet information related to leases was as follows: December 31, December 31, Operating lease right-of-use asset $ 646 $ 873 Operating lease liability, current $ (256 ) $ (228 ) Operating lease liability, noncurrent (428 ) (683 ) Total operating lease liabilities $ (684 ) $ (911 ) Future maturities of operating lease liabilities as of December 31, 2023 were as follows: 2024 302 2025 310 2026 144 Total lease payments 756 Less: imputed interest (72 ) Present value of operating lease liabilities $ 684 Other information: Cash paid for operating leases for the year ended December 31, 2023 $ 293 Cash paid for operating leases for the year ended December 31, 2022 $ 284 Remaining lease term - operating leases (in years) 2.50 Average discount rate - operating leases 8.0 %

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2023
Stockholders' Equity [Abstract]
Stockholders' Equity	9. Stockholders’ Equity The Company’s current Amended and Restated Certificate of Incorporation dated February 18, 2014 authorizes the issuance of 130,000,000 shares of common stock and 20,000,000 shares of preferred stock, both with a par value of $0.001 per share. With respect to the preferred stock, 4,500,000 shares are designated Series A Preferred Stock and 491,222 shares are designated Series B Preferred Stock. As of December 31, 2023 and 2022, there were no shares of Series A Preferred stock or Series B Preferred Stock issued and outstanding. Initial Public Offering On April 26, 2022, the Company’s Registration Statement relating to the IPO was declared effective by the SEC. The IPO consisted of 320,000 shares of common stock, par value $0.001 per share at a public offering price of $50.00 per share. Pursuant to the Underwriting Agreement dated April 26, 2022, between the Company, The Benchmark Company, LLC (“Benchmark”) and Valuable Capital Limited (together with Benchmark, the “Underwriters”), the Company granted the Underwriters warrants to purchase a total of 9,600 shares of the Company’s common stock at an exercise price of $50.00 per share. The warrants expire on the fifth anniversary of the commencement of sales under the IPO. On April 27, 2022, the shares of the Company’s common stock began trading on the Nasdaq Capital Market LLC under the symbol “TNON.” On April 29, 2022, the IPO closed, and the Company received approximately $13.8 million in net proceeds from the IPO after deducting the underwriting discount and commission and other estimated IPO expenses payable by the Company. As a result of the completion of the IPO, the Company converted the entirety of the outstanding principal and accrued interest of the convertible notes payable to 395,542 shares of the Company’s common stock. On April 29, 2022, as result of the completion of the IPO, the Company converted all shares of Series A and Series B Preferred Stock to 269,334 shares of the Company’s common stock at the conversion rate detailed below and issued the common stock to the preferred stockholders. Concurrent with the completion of the IPO and in accordance with the Amended and Restated Exclusive Sales Representative Agreement executed in May 2021, the counterparty to the agreement received anti-dilution protections to maintain ownership of 3.0% of the fully diluted equity of the Company through the date of an initial public offering and was issued 31,235 shares of the Company’s common stock to the Representative, fully satisfying the Company’s obligations. Also, as a result of the completion of the IPO, the Company issued 8,574 shares of its common stock to a consultant. The value of these shares issued at the IPO price of $50.00 per share was charged to operating expenses in the Company’s consolidated financial statements. Registered Offering On June 16, 2023, the Company closed the Registered Offering of a total of 1,000,000 units (the “Units”) for proceeds, net of issuance costs, of $4,808, with each Unit consisting of (i) one share of the Company’s common stock, and (ii) two warrants, each warrant to purchase one share of the Company’s common stock at an exercise price equal to $5.60 per share (the “Offering Warrants”). The Offering Warrants were exercisable upon issuance and will expire five years from the date of issuance. Per the terms of the Offering Warrants, the exercise price reset on July 16, 2023 to $3.146 per share. At-the-Market Offering Program On May 4, 2023, the Company entered into an Equity Distribution Agreement to establish an at-the-market offering program, under which the Company may sell from time to time, at its option, shares of its common stock having an aggregate gross sales price of $5.5 million. The Company is required to pay the Sales Agents a commission of 3% of the gross proceeds from the sale of shares and has also agreed to provide the Sales Agents with customary indemnification rights. During the year ended December 31, 2023, 232,100 shares of the Company’s common stock were sold under the program at a weighted-average price of $2.27 per share with aggregate net proceeds of $495. Equity Line of Credit On July 24, 2023, the Company entered into a purchase agreement (“Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), under which, subject to specified terms and conditions, the Company may sell to Lincoln Park up to $10 million of shares of common stock from time to time during the term of the Purchase Agreement. On September 22, 2023 (the “Commencement Date”), the Company filed a registration statement with the Securities and Exchange Commission (the “SEC”), covering the resale of shares of common stock issued to Lincoln Park under the Purchase Agreement. Beginning on the Commencement Date and for a period of 24 months thereafter, under the terms and subject to the conditions of the Purchase Agreement, from time to time, at the Company’s discretion, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to $10 million of shares of common stock, subject to certain limitations set forth in the Purchase Agreement. Specifically, from time to time from and after the Commencement Date, the Company may, at its discretion, direct Lincoln Park to purchase on any single business day on which the closing price of its common stock on The Nasdaq Capital Market (“Nasdaq”) is equal to or greater than $1.50 up to 10,000 shares of common stock (a “Regular Purchase”); provided, that the Company may direct Lincoln Park to purchase in a Regular Purchase (i) up to 12,500 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least $15.00 per share and (ii) up to 15,000 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least $25.00 per share. In no case, however, will Lincoln Park’s commitment with respect to any single Regular Purchase exceed $500,000; provided, that the parties may mutually agree at any time to increase the maximum number of shares of common stock the Company may direct Lincoln Park to purchase in any single Regular Purchase to up to 100,000 shares or any number of shares that shall not exceed 4.99% of the then outstanding shares of common stock. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring after the date of the Purchase Agreement with respect to our common stock. The purchase price per share for each such Regular Purchase will be based on prevailing market prices of the Company’s common stock immediately preceding the time of sale, as determined under the Purchase Agreement. Voting rights The holders of vested shares of common stock are entitled to vote on any matter submitted to a vote of the stockholders and each such holder is entitled to one vote per share of common stock held. The holders of Series A and Series B Preferred Stock were entitled to vote together with the common stock as a single class on any matter submitted to a vote of the stockholders. Holders of Series A and Series B Preferred Stock were entitled to the number of votes equal to the number of common stock issuable upon conversion of their respective Series A and Series B Preferred Stock at the time such shares are voted. The holders of a majority of the preferred stock had additional voting rights as specified in the Company’s Amended and Restated Certificate of Incorporation, as amended. Equity awards In 2012, the Board of Directors of the Company (the “Board”) approved the Tenon Medical, Inc. 2012 Equity Incentive Plan (the “2012 Plan”). The 2012 Plan provided for the issuance of common stock options, appreciation rights, and other awards to employees, directors, and consultants. Options issued under the 2012 Plan generally vest over a period of two to four years and have a 10-year expiration date. On January 10, 2022 and February 2, 2022, the Board and stockholders, respectively, of the Company approved the Tenon Medical, Inc. 2022 Equity Incentive Plan (the “2022 Plan”), which was effective on April 25, 2022. The initial number of shares of common stock subject to awards under the 2022 Plan was 160,000. The 2022 Plan calls for automatic annual increases in the number of shares available for issuance equal to the least of (a) 110,000 shares, (b) 4% of the total number of shares of all classes of common stock outstanding on the last day of the immediately preceding fiscal year, or (c) such number determined by the 2022 Plan administrator no later than the last day of the immediately preceding fiscal year. Annual increases will continue until the tenth anniversary of the earlier of the Board or stockholder approval of the 2022 Plan, which is January 10, 2032. Upon the effective date of the 2022 Plan, the Board terminated the 2012 Plan such that no new equity awards will be issued by the 2012 Plan. Compensation expense for the years ended December 31, 2023 and 2022 includes the portion of awards vested in the periods for all equity-based awards granted, based on the grant date fair value. estimated using a Black-Scholes option valuation model. Grant date fair value for restricted stock units is estimated using the fair value of the Company’s common stock on the date of grant. Grant date fair value for stock options is estimated using a Black-Scholes option valuation model using the weighted-average assumptions in the table below: Years ended 2023 2022 Expected volatility 63.89 % 57.68 % Dividend yield 0 % 0 % Risk-free interest rate 4.28 % 3.34 % Expected term in years 5.85 5.85 Estimates of fair value are not intended to predict actual future events or the value ultimately realized by employees who receive equity awards, and subsequent events are not indicative of the reasonableness of the original estimates of fair value made by the Company in accordance with authoritative guidance. A summary of the Company’s share option and restricted stock unit activity under its plans is as follows: Options RSUs Number Weighted- Weighted- Number of Weighted Balance as of December 31, 2021 72,744 $ 53.18 7.12 — Granted 17,145 $ 22.98 131,858 $ 79.29 Balance as of December 31, 2022 89,889 $ 47.42 8.10 131,858 $ 79.29 Granted 15,050 $ 12.91 7,500 $ 2.91 Released — — (61,200 ) $ 82.04 Canceled (2,850 ) $ 39.87 (1,242 ) $ 88.60 Balance as of December 31, 2023 102,089 $ 42.54 7.41 76,916 $ 69.50 Exercisable at December 31, 2023 70,634 $ 48.66 6.86 The weighted-average grant-date fair value of options granted during the years ended December 31, 2023 and 2022 was $7.63 and $12.90, respectively. The aggregate intrinsic value of outstanding options at December 31, 2023 was $0. The aggregate intrinsic value is equal to the difference between the exercise price of the underlying option and the fair value of the Company’s common stock for in-the-money options. As of December 31, 2023, total compensation cost not yet recognized related to unvested options was $414, which is expected to be recognized over a weighted-average period of 0.99 years, and total compensation costs not yet recognized related to unvested RSUs was $4,773, which is expected to be recognized over a weighted-average period of 1.40 years. The following table sets forth stock-based compensation expense recognized for the years ended December 31, 2023 and 2022: Years ended 2023 2022 Research and development $ 1,504 $ 995 Sales and marketing 217 117 General, and administrative 2,424 1,785 Total stock-based compensation expense $ 4,145 $ 2,897 At December 31, 2023, there were 37,486 shares available for issuance under the 2022 Plan. Warrants In April 2022, as noted above, the Company granted the Underwriters warrants to purchase a total of 9,600 shares of the Company’s common stock. The warrants are immediately exercisable at an exercise price of $50.00 per share and expire on the fifth anniversary of the commencement of sales under the IPO. The fair value of the warrants on the grant date was $27.50 per warrant, which was calculated using a Black-Scholes option valuation model with an expected term of 5.00 years, expected volatility of 62.55%, dividend yield of 0%, and risk-free interest rate of 2.92%. The Company recorded the fair value of these warrants of approximately $264 as an issuance cost to additional paid-in capital in 2022. As the IPO issuance costs were also recorded to additional paid-in capital, the net impact was $0. In June 2023, as noted above, in connection with the Registered Offering, the Company issued Offering Warrants to purchase a total of 2,000,000 shares of the Company’s common stock. The Offering Warrants were exercisable upon issuance at an exercise price of $5.60 per share and will expire five years from the date of issuance. Per the terms of the Offering Warrants, the exercise price of the Offering Warrants reset on July 16, 2023, to a price equal to the greater of (i) $2.80 per share and (ii) 100% of the last VWAP (as defined in the Warrants) on July 14, 2023, which was $3.146 per share. The fair value of the Offering Warrants on the grant date was approximately $3,164, or $1.58 per warrant, which was calculated using a Monte-Carlo simulation to estimate the final exercise price, which is considered a Level 3 fair value measurement, using as inputs; the starting value of $3.00 per share, the Company’s VWAP on June 16; an assumed daily distribution of returns; a mean daily return of 5.18%; a short-term annual volatility of 100% and a standard deviation of 6.3%. The model used Black-Scholes to then calculate the estimated fair value of the Offering Warrants, using an estimated time to maturity of 4.9 years, a risk-free interest rate of 3.99% and a long-term volatility of 60%. Based on the accounting guidance under ASC 815, the Company determined that the Offering Warrants did not meet the criteria for classification as equity as of June 30, 2023. Accordingly, the Company classified the fair value of the Offering Warrants as a liability. As of July 16, 2023, with the resolution of the reset value, the Company has determined that the Offering Warrants do meet the criteria for classification as equity and the fair value of the Offering Warrants has been reclassified to additional paid-in capital on the Company’s consolidated balance sheet as of that date. In November 2023, in connection with the issuance of the Convertible Notes, the Company issued warrants to purchase a total of 45,000 shares of the Company’s common stock at an exercise price equal to $1.94 per share. The warrants expire five years from the issuance date. The fair value of the warrants on the grant date was $1.29 per warrant, which was calculated using a Black-Scholes option valuation model with an expected term of 5.00 years, expected volatility of 68.89%, dividend yield of 0%, and risk-free interest rate of 4.41%. The Company recorded the fair value of these warrants of approximately $58 as an issuance cost to additional paid-in capital in 2023.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Sales Representative Agreement In April 2020, the Company entered into an Exclusive Sales Representative Agreement, under which the counterparty to the agreement (the “Representative”) received exclusive rights to market, promote, and distribute The Catamaran System in the United States and Puerto Rico. The agreement is for an initial period of five years, and automatically renews for an additional five years unless written notice is given by either party prior to April 27, 2023. The agreement provides for a bonus to be paid to the Representative upon an acquisition or IPO. In May 2021, the Company entered into an Amended and Restated Exclusive Sales Representative Agreement (the “Restated Sales Agreement”). In connection with the amended agreement, the Company paid $500 cash and issued 53,757 shares of common stock to the Representative, for which the Company recorded a combined total of approximately $880 as sales and marketing expense. In addition, the Representative received anti-dilution protections to maintain ownership of 3.0% of the fully diluted equity of the Company through the date of an initial public offering. In October 2021, the Company issued 4,445 shares of common stock with a fair value of approximately $333 to the Representative in accordance with the anti-dilution provision. In April 2022, the Company issued 31,235 shares of common stock to the Representative in accordance with the anti-dilution provision, fully satisfying the Company’s obligations. The Restated Sales Agreement restructured the calculation of the bonus paid to the Representative upon an acquisition, removed the bonus payable upon an IPO, and allows the Company to terminate the Restated Sales Agreement as long as the bonus paid to the Representative is at least $6,000. On October 6, 2022, the Company entered into the Terminating Amended and Restated Exclusive Sales Representative Agreement (the “Termination Agreement”) with the Representative, which terminated the Restated Sales Agreement. In accordance with the Termination Agreement, (i) the Company paid the Representative $1,000 in cash; and (ii) the Company agreed to pay the Representative (a) $85 per month during the six months after the date of the Termination Agreement in return for efforts by the Representative to transition operations to the Company, (b) 20% of net sales of the product sold in the United States and Puerto Rico until December 31, 2023 and (c) after December 31, 2023, 10% of net sales until such time as the aggregate amount paid to the Representative under this clause (c) and clause (b) above equal $3,600. In the event of an acquisition of the Company, the Company will pay the Representative $3,600 less previous amounts paid pursuant to clause (b) and clause (c) above. The Company recorded a charge of $1,000 for the payment to the Representative in the fourth quarter of 2022 and expensed the $85 per month charges as incurred over the six-month period. For payments under clause (b) and clause (c) above, the Company estimated the fair value of the liability using level 3 hierarchy inputs based on a Monte Carlo simulation of future revenues with a 25% quarterly estimated standard deviation of growth rates and a 10% probability of dissolution, discounted at an estimated discount rate of 15.4%. Based on the Company’s fair value analysis, a total of $2,611 was charged to sales and marketing expense in the consolidated statements of operations and comprehensive loss and recorded as accrued commissions in the consolidated balance sheets. A reconciliation of the liability under clause (b) and clause (c) for the year ended December 31, 2023 is as follows: 2023 Balance at January 1, 2023 $ 2,560 Amounts paid during 2023 (592 ) Accretion 409 Balance at December 31, 2023 $ 2,377 Per the terms of the Termination Agreement, the Company ultimately expects to expense $3,600 under clause (b) and clause (c). Simultaneously with the execution of the Termination Agreement, the Company entered into a Consulting Agreement dated October 6, 2022, with the Representative (the “Consulting Agreement”). Under the terms and conditions of the Consulting Agreement, the Representative is tasked with organizing, recruiting, training, and coordinating the Company’s Clinical Specialist program, Physician Education program and Sales Education program as more specifically described in the Consulting Agreement. The term of the Consulting Agreement was from October 6, 2022, until October 5, 2023, when it terminated in accordance with the terms of the Consulting Agreement. In consideration for the services to be provided, the Company paid the Representative a base consulting fee of $700 per year, payable in monthly instalments, along with additional compensation of $62.5 per quarter, if certain sales targets were met, for four quarters; along with any travel and related out-of-pocket expenses incurred by the Representative in connection with the performance of the services. Litigation In the normal course of business, the Company may possibly be named as a defendant in various lawsuits.

Concentrations of Risk

Concentrations of Risk	12 Months Ended
	Dec. 31, 2023
Concentrations of Risk [Abstract]
Concentrations of Risk	11. Concentrations of Risk Credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances at financial institutions located in California and Switzerland. Accounts at the U.S. financial institutions are secured by the Federal Deposit Insurance Corporation. At times, balances may exceed federally insured limits. The Company has not experienced any losses in such accounts. Management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents. The Company grants unsecured credit to its customers based on an evaluation of the customer’s financial condition and a cash deposit is generally not required. Management believes its credit policies do not result in significant adverse risk and historically has not experienced significant credit-related losses. Currency risk The Company’s subsidiary, Tenon Technology AG, realizes a portion of its expenses in Swiss francs. Consequently, certain assets and liabilities are exposed to foreign currency fluctuations. At December 31, 2023 and 2022, approximately $741 and $8, respectively, of the Company’s net monetary assets were denominated in Swiss francs. The Company has not entered into any hedging transactions to reduce the exposure to currency risk.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
Income Taxes	12. Income Taxes The components of loss before income taxes are as follows: Years ended 2023 2022 United States $ (15,570 ) $ (18,886 ) International (11 ) (30 ) Loss before income taxes $ (15,581 ) $ (18,916 ) The components of current income tax expense are as follows: Years ended 2023 2022 Federal $ — $ — State — 1 Foreign — — Total income tax expense $ — $ 1 A reconciliation of the expected tax computed at the U.S. statutory federal income tax rate to the total provision for income taxes for the years ended December 31, 2023 and 2022 is as follows: Years ended 2023 2022 Statutory rate (21 )% (21 )% State taxes, net of federal benefit (7 )% (7 )% Non-deductible differences 3 % 1 % Change in valuation allowance 25 % 27 % Provision for taxes — — Significant components of the Company’s net deferred tax assets at December 31, 2023 and 2022 are as follows: Years ended 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 9,504 $ 7,001 Credit carryforwards 220 109 Fixed assets 52 — Accruals and reserves 111 126 Stock-based compensation 1,802 843 Intangibles 220 244 Operating lease liability 188 254 Capitalized research and development 514 274 Total deferred tax assets 12,611 8,851 Valuation allowance (12,433 ) (8,564 ) Net deferred tax assets 178 287 Deferred tax liabilities: Fixed assets — (44 ) Operating lease right of use (178 ) (243 ) Total deferred tax liabilities (178 ) (287 ) Net deferred tax assets $ — — In assessing the realizability of deferred tax assets at December 31, 2023, management considered whether it is more likely than not that some portion or all of the deferred tax assets will be realized, and determined that a valuation allowance was required for those deferred tax assets that are not expected to provide future tax benefits. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. At December 31, 2023, the Company has available net operating loss carryforwards of approximately $33,866 for federal income tax purposes, of which approximately $33,644 was generated after 2017 and can be carried forward indefinitely under the Tax Cuts and Jobs Act. The remaining federal net operating loss of approximately $222, which was generated prior to 2018, will start to expire in 2034 if not utilized. At December 31, 2023, the net operating loss carryforwards for state purposes are approximately $32,147 and will begin to expire in 2032 if not utilized. In addition, the Company had foreign net operating loss carryforwards of approximately $1,378 at December 31, 2023 that will start to expire in 2024 if not utilized. The Company had credit carryforwards of approximately $214 for federal income tax purposes. The federal tax credits will begin to expire in 2041. The Company also had credit carryforwards of approximately $101 for California income tax purposes. These credits have no expiration. The Company has not completed a study to determine whether any ownership change per the provisions of Section 382 of the Internal Revenue Code of 1986, as amended, as well as similar state provisions, has occurred. Utilization of the Company’s net operating loss and income tax credit carryforwards may be subject to a substantial annual limitation due to ownership changes that may have occurred or that could occur in the future. These ownership changes may limit the amount of the net operating loss and income tax credit carryover that can be utilized annually to offset future taxable income. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders. Uncertain tax positions In accordance with authoritative guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. The following shows the changes in the gross amount of recognized tax benefits: Years ended 2023 2022 Unrecognized tax benefits, beginning of year $ 38 $ — Increases related to prior year tax positions 5 12 Decreases related to prior year tax positions — — Increases related to current year tax positions 36 26 Unrecognized tax benefits, end of year $ 79 $ 38 The Company recognizes interest and penalties related to unrecognized tax positions within the income tax expense line in the accompanying consolidated statements of operations and comprehensive loss. The Company does not anticipate that its total unrecognized tax benefits will significantly change due to settlement of examination or the expiration of statute of limitations during the next 12 months. Due to the full valuation allowance at December 31, 2023, current adjustments to the unrecognized tax benefit will have no impact on our effective income tax rate. The Company currently has no federal or state tax examinations in progress nor has it had any federal or state tax examinations since its inception. As a result of the Company’s net operating loss and credit carryforwards, all of its years are subject to federal and state examination.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events On February 20, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors, pursuant to which the Company agreed to sell, issue and deliver to these investors, in a private placement offering (the “Offering”), a total of 172,239 shares of the Company’s Series A Preferred Stock and warrants (the “Warrants”) to purchase 258,374 shares of common stock, par value $0.001 per share, of the Company (“Common Stock”) at an exercise price equal to $1.2705 per share for an aggregate offering price of $2,605,000. Additionally, on February 20, 2024, the Investors agreed to a complete prepayment of the Company’s obligations under the Convertible Notes, including accrued interest, in exchange for 84,729 shares of Series A Preferred Stock and warrants to purchase 157,094 shares of our common stock at $1.2705 per share and the Convertible Notes were cancelled. The Warrants are immediately exercisable and expire five years from the date of issuance. The Series A Preferred Stock is convertible, at any time, at the option of the holder into shares of Common Stock. Each share of Series A Preferred Stock shall be convertible, at any time after the date of issuance, at the option of the holder thereof (or, upon a Required Conversion (as defined below), at the option of the Corporation), into that number of shares of Common Stock determined by dividing the Stated Value (as defined below) for such share of Series A Preferred Stock by the Conversion Price (as defined below). “Stated Value” means for any share of Series A Preferred Stock, an amount equal to the product of (x) $15.125 multiplied by (y) the sum of 1 plus the product of (A) 0.06 multiplied by (B) a fraction equal to the number of days that such share of Series A Preferred Stock has been issued divided by 365. “Conversion Price” means (i) for the shares of Series A Preferred Stock issued on the Closing Date, $1.5125 and (ii) for each share of Series A Preferred Stock issued thereafter, an amount equal to the greater of (x) $1.5125 and the average of the VWAPs for the 10 Trading Days prior the issuance date of such share of Series A Preferred Stock, in each case subject to adjustment as set forth herein. On any date that ten out of the last 15 daily VWAPs of the Common Stock is 250% higher than the Conversion Price on such date, then the Company will have the right to require 50% of the Preferred Stock to be converted into shares of Common Stock. Additionally, on and after the time on which the Company has $2.25 million in revenues in any single financial quarter, the Company will have the right to require 50% of the Preferred Stock to be converted into shares of Common Stock (a “Required Conversion”). No dividends are payable on the Series A Preferred Stock. The Series A Preferred Stock will vote together with the Common Stock on all matters other than as required by law; provided however that any additional shares underlying the Series A Preferred Stock as a result of the anti-dilution provision described below shall not vote on an “as converted” basis and shall only vote when issued upon conversion. Notwithstanding the foregoing, the vote of an individual holder of Series A Preferred Stock (and underlying Common Stock) shall be capped at 9.99% (or 4.99% if selected by the holder). The Conversion Price is subject to anti-dilution adjustment as the result of any subdivision, combination of shares or recapitalization, stock dividends, stock splits and similar transactions affecting the Common Stock. In addition, the Series A Preferred Stock will have weighted average anti-dilution protection providing for adjustment of the Conversion Price in the event of issuance of, or commitments to issue, Common Stock for less than the Conversion Price then in effect immediately prior to such issue or sale (a “Dilutive Issuance”), subject to customary exceptions; provided however the anti-dilution for Dilutive Issuances shall not be operative until the stockholders of the Company have approved the terms of the Series A Preferred Stock. Upon any liquidation or winding up of the Company (a “Liquidation”), the holders of Series A Preferred Stock will be entitled to receive in preference to any other class or series of the Company’s equity securities the greater of (i) the Stated Value plus accrued and unpaid dividends and (ii) what would be paid if the Series A Preferred Stock plus accrued and unpaid dividends had been converted into Common Stock. A consolidation or merger of the Company or sale or transfer of all or substantially all of its assets, or any transaction which results in the stockholders of the Company owning less than 50% of the equity or voting power of the surviving entity (excluding the issuance of Common Stock in any financing transaction unless more than 50% of the Company’s shares are issued to one stockholder or a number of stockholders who act as a one group) shall be deemed a Liquidation (a “Deemed Liquidation”) with respect to the shares of Series A Preferred Stock of any holder who opts to have such occurrence treated as a Deemed Liquidation; provided that if the liquidation preference payable on a Deemed Liquidation is less than 110% of the stated value of the Series A Preferred Stock, the dividend rate on any accrued and unpaid dividends payable with respect to such Deemed Liquidation will increase to 10%. All liquidation preferences payable in respect of a Deemed Liquidation will be payable in shares of Common Stock based on the closing price of the Common Stock on the date of such Deemed Liquidation. Consent of the majority of the holders will be required to (i) amend the Certificate of Incorporation or Bylaws of the Company so as to adversely alter the rights, preferences, privileges of the Series A Preferred Stock, (ii) create any new class of shares pari passu or senior to the Series A Preferred Stock or increase or decrease the number of authorized shares of Common Stock or preferred stock, (iii) pay or declare any dividend on Common Stock or other junior securities, or incur indebtedness in any single transaction in excess of $1 million or (iv) redeem, purchase or otherwise acquire any share or shares of preferred stock or Common Stock (other than (a) the repurchase of shares of Common Stock pursuant to a written benefit plan or employment or consulting agreement, or (b) the repurchase of any equity securities in connection with the Company’s right of first offer with respect to those securities contained in any written agreement with the Company). As of March 29, 2024, with the issuance of the Series A Preferred Stock, the conversion of the Convertible Notes, and proceeds from the Company’s ATM and ELOC facilities, the Company believes that its Stockholders’ Equity will exceed $2.5 million and will therefore meet the minimum stockholder equity amount required by the Nasdaq Stock Market, LLC.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2023
Summary of Significant Accounting Principles [Abstract]
Basis of presentation	Basis of presentation The accompanying consolidated financial statements have been prepared on the accrual basis in accordance with generally accepted accounting principles as promulgated in the United States of America (“U.S. GAAP”).
Going concern uncertainty and liquidity requirements	Going concern uncertainty and liquidity requirements The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. There is substantial doubt about the Company’s ability to continue as a going concern for one year after the date that these financial statements are issued. Since inception, the Company has incurred losses and negative cash flows from operations. Management expects to incur additional operating losses and negative cash flows from operations in the foreseeable future as the Company continues its product development programs and the commercialization of The Catamaran System. Based on the Company’s expected level of revenues and expenditures, the Company believes that its existing cash and cash equivalents as of December 31, 2023 will not provide sufficient funds to enable it to meet its obligations for a period of at least twelve months from the date of the filing of these consolidated financial statements. The Company plans to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations (see Note 13). The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Use of estimates	Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, obsolescence of inventory, the fair value of accrued commissions and stock-based compensation.
Reverse Stock Splits	Reverse Stock Splits On April 6, 2022, the Company effected a 1-for-2 reverse stock split (the “2022 Reverse Stock Split”) by filing an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Delaware Secretary of State. The 2022 Reverse Stock Split combined every two shares of our common stock issued and outstanding immediately prior to effecting the 2022 Reverse Stock Split into one share of common stock. Similarly, shares of Series A and Series B Preferred Stock became convertible into common stock at a conversion rate of one-to-0.5, subject to adjustments for stock dividends, splits, combinations, and similar events. No fractional shares were issued in connection with the 2022 Reverse Stock Split. On November 2, 2023, the Company effected a 1-for-10 reverse stock split (the “2023 Reverse Stock Split”) by filing an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Delaware Secretary of State. The 2023 Reverse Stock Split combined every ten shares of our common stock issued and outstanding immediately prior to effecting the 2023 Reverse Stock Split into one share of common stock. No fractional shares were issued in connection with the 2023 Reverse Stock Split. All historical share and per share amounts reflected throughout this document have been adjusted to reflect the 2022 Reverse Stock Split and the 2023 Reverse Stock Split. The authorized number of shares and the par value per share of the Company’s common stock were not affected by the 2022 Reverse Stock Split or the 2023 Reverse Stock Split.
Segments	Segments The Company operates in one business segment. Although the Company’s Swiss subsidiary is located in a different geographical area, management uses one measurement of profitability and does not segregate its business for internal reporting.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments with maturities of 90 days or less at the date of purchase to be cash equivalents.
Investments	Investments The Company classifies its investments in marketable securities as available-for-sale and records them at fair value in its consolidated balance sheets. The net unrealized gains and losses are recorded as a separate component of stockholders’ equity. Realized gains and losses are recorded in the consolidated statements of operations and comprehensive loss. The Company determines any realized gains or losses on the sale of marketable debt securities on a specific identification method and records such gains and losses as a component of other income (expense) net.
Accounts receivable and allowance for doubtful accounts	Accounts receivable and allowance for doubtful accounts Accounts receivable are derived from products delivered to customers and are stated at their net realizable value. The Company records an allowance for estimated uncollectible accounts in an amount approximating anticipated losses. Individual uncollectible accounts are written off against the allowance when collection of the individual accounts appears doubtful. In determining the amount of the allowance, the Company considers its historical level of credit losses. The Company also makes judgments about the creditworthiness of significant customers based on ongoing credit evaluations, and the Company assesses current economic trends that might impact the level of credit losses in the future. Historically, the Company has had no significant write-offs of accounts receivable. However, since the Company cannot reliably predict future changes in the financial stability of its customers, it cannot guarantee that its allowances will continue to be adequate. If actual credit losses are significantly greater than the allowance, the Company would increase its general and administrative expenses and increase its reported net losses. As of December 31, 2023 and 2022, the Company’s allowance for expected credit losses was $0.
Inventory	Inventory Inventory is stated at lower of cost or net realizable value. The Company establishes the inventory basis by determining the cost based on standard costs approximating the purchase costs on a first-in, first-out basis. The excess and obsolete inventory is estimated based on future demand and market conditions. Inventory write-downs are charged to cost of goods sold. As of December 31, 2023 and 2022, inventory consisted of finished goods and raw materials.
Deferred offering costs	Deferred offering costs Deferred offering costs, which consist of direct incremental legal, consulting, banking, and accounting fees relating to the Company’s future offerings, are capitalized, and are offset against proceeds received upon the effectiveness of the offering. In the event an anticipated offering is terminated, deferred offering costs will be expensed.
Fixed assets, net	Fixed assets, net Fixed assets are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Equipment, computers, software, and furniture and fixtures are depreciated over periods ranging from three to seven years, and leasehold improvements over the shorter of the lease term or the life of the asset. Construction in progress pertains to the cost of individual components of a custom instrument set used for surgical placement of the Company’s products that have not yet been placed into service. The cost of maintenance and repairs is charged to expense as incurred; significant renewals and betterments are capitalized. Deductions are made for retirements resulting from renewals or betterments.
Leases	Leases The Company leases its headquarters in Los Gatos, California. At the inception of a contract, the Company assesses whether that contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefit from the use of the asset throughout the term, and (3) whether the Company has the right to direct the use of the asset. At inception of a lease, the Company allocates the consideration in the contract to each lease and non-lease component based on the component’s relative stand-alone price to determine the lease payments. Lease and non-lease components are accounted for separately. Leases are classified as either finance leases or operating leases based on criteria in FASB ASC 842, “Leases”. The Company’s facility lease is classified as an operating lease. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease’s commencement date based on the present value of lease payments over the lease term. When a lease did not provide an implicit rate, the Company used its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The Company has elected not to recognize ROU assets and lease liabilities for short-term operating leases that have a term of 12 months or less. Lease expense for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses in the consolidated statements of operations and comprehensive loss.
Long-lived assets	Long-lived assets The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist that warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management’s estimate of the asset’s ability to generate positive income from operations and positive undiscounted cash flow in future periods as well as the strategic significance of the assets to the Company’s business objectives.
Fair value measurements	Fair value measurements In accordance with Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, fair value is the price that would be received from selling an asset or paid to transfer a liability (i.e., the exit price) in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels based on the inputs as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reported date. Level 2 – Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reported date. The nature of these financial instruments includes cash instruments for which quoted prices are available but are traded less frequently, derivative instruments whose fair values have been derived using a model where inputs to the model are directly observable in the market and instruments that are fair valued using other financial instruments, the parameters of which can be directly observed. Level 3 – Instruments that have little to no pricing observability as of the measurement date. These financial instruments are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment or estimation. The degree of judgment exercised by the Company in determining fair value is greatest for assets categorized in Level 3. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety is determined by the lowest level input that is significant to the fair value measurement.
Income Taxes	Income taxes Income taxes are recorded in accordance with Financial Accounting Standards Board (“FASB”) ASC Topic 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. Under this method, the Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect when the differences are expected to reverse. Valuation allowances are provided when necessary to reduce net deferred tax assets to the amount that is more likely than not to be realized. Based on the available evidence, the Company is unable, at this time, to support the determination that it is more likely than not that its deferred tax assets will be utilized in the future. Accordingly, the Company recorded a full valuation allowance as of December 31, 2023 and 2022. The Company intends to maintain valuation allowances until sufficient evidence exists to support its reversal. Current income taxes are based upon the year’s income taxable for federal, state, and foreign tax reporting purposes. Deferred income taxes are provided for certain income and expenses, which are recognized in different periods for tax and financial reporting purposes. The Company’s policy is not to record deferred income taxes on the undistributed earnings of foreign subsidiaries that are indefinitely reinvested in foreign operations.
Revenue recognition	Revenue recognition The Company’s revenue is derived from the sale of its products to medical groups and hospitals in the United States. Revenue is recognized when control is transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for the goods or services, using the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied. The Company generates revenue from the sale of products to hospitals or medical facilities where its products are delivered in advance of a procedure. The performance obligation is the delivery of the products along with the completion of the surgery and therefore, revenue is recognized upon delivery to the customers and completion of the surgery, net of rebates and price discounts. The Company accounts for rebates and price discounts as a reduction to revenue, calculated based on the terms agreed to with the customer. Historically, there have been no significant rebates or price discounts. Sales prices are specified prior to the transfer of control to the customer, via either the customer contract, agreed price list, purchase order, or written communication with the customer. Prior to October 2022, the Company had an agreement in place with a national distributor, which included standard terms that did not allow for payment contingent on resale of the product, obtaining financing, or other terms that could impact the distributor’s payment obligation. The Company billed and collected directly with the end-user customers and recognized revenue based on the gross sales price. For direct sales to end-user customers, the Company’s standard payment terms are generally net 30 days. The Company offers its standard warranty to all customers and does not sell any warranties on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and includes an offer to replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records them as a charge to cost of goods sold. Contract modifications generally do not occur during the performance of the Company’s contracts. Payments received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the consolidated balance sheets. As of December 31, 2023 and 2022, there were no remaining performance obligations that would give rise to deferred revenue. Sales commissions are recorded in sales and marketing expenses during the same period as the corresponding revenues.
Research and development	Research and development The Company engages in improving existing products and new product development efforts. Research and development expenses relating to these efforts are expensed as incurred.
Stock-based compensation	Stock-based compensation The Company accounts for all stock-based compensation awards using a fair-value method on the grant date and recognizes the fair value of each award as an expense over the requisite service period. The Company recognizes compensation costs related to stock-based awards granted to employees, directors, and consultants including stock options, based on the estimated fair value of the awards on the date of grant. We estimate the grant date fair value, and the resulting stock-based compensation, using the Black-Scholes option-pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Black-Scholes option-pricing model requires the use of subjective assumptions to determine the fair value of stock-based awards. These assumptions include: Expected Term Expected Volatility Risk-Free Interest Rate Expected Dividend The Company account for forfeitures as they occur. The Company’s board of directors intends all options granted to be exercisable at a price per share not less than the per share fair value of our common stock underlying those options on the date of grant. Prior to the Company’s initial public offering, the estimated fair value of its common stock was determined at each valuation date by a third-party independent valuation firm in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. These valuations took into account numerous factors, including developments at our company and market conditions. The May 21, 2021 valuation used a hybrid method which combines the Probability Weighted Expected Return Method (“PWERM”) with the OPM. The PWERM considers a set of discrete potential liquidity scenarios for the Company, the value common stock would receive in each scenario, and the time required and risk inherent in achieving those values. The May 21, 2021 valuation examined the following scenarios for the Company: (i) an IPO; (ii) remaining private and raising capital; and (iii) dissolution. Within the IPO scenario, 100% weighting was placed on the Market Approach for determining the enterprise value. The Market Approach assumes that businesses operating in the same industry will share similar characteristics, and therefore a comparison of the business to similar businesses whose financial information is publicly available may provide a reasonable basis to estimate a subject business’s value. The equity value in the IPO scenario was estimated considering guideline IPOs, the anticipated size of the Company’s offering, and forecasted cash and debt. The estimated common stock value as of the IPO was present valued using a discount rate of 22.4% based on Company’s WACC, less an adjustment of 2.0% to reflect the risk reduction of an IPO event. The August 31, 2021 valuation used a hybrid method which combines the Probability Weighted Expected Return Method (“PWERM”) with the OPM. The PWERM considers a set of discrete potential liquidity scenarios for the Company, the value common stock would receive in each scenario, and the time required and risk inherent in achieving those values. The August 31, 2021 valuation examined the following scenarios for the Company: (i) an IPO; (ii) remaining private and raising capital; and (iii) dissolution. Within the IPO scenario, 100% weighting was placed on the Market Approach for determining the enterprise value. The Market Approach assumes that businesses operating in the same industry will share similar characteristics, and therefore a comparison of the business to similar businesses whose financial information is publicly available may provide a reasonable basis to estimate a subject business’s value. The equity value in the IPO scenario was estimated considering guideline IPOs, the anticipated size of the Company’s offering, and forecasted cash and debt. The estimated common stock value as of the IPO was present valued using a discount rate of 32.0% based on Company’s WACC, less an adjustment of 5.0% to reflect the risk reduction of an IPO event. The October 28, 2021 valuation used a hybrid method which combines the Probability Weighted Expected Return Method (“PWERM”) with the OPM. The PWERM considers a set of discrete potential liquidity scenarios for the Company, the value common stock would receive in each scenario, and the time required and risk inherent in achieving those values. The October 28, 2021 valuation examined the following scenarios for the Company: (i) an IPO; (ii) remaining private and raising capital; and (iii) dissolution. Within the IPO scenario, 100% In determining the enterprise value within the remain private scenario, 100% weighting was applied to the DCF Method under the income approach, in the same manner as in the December 31, 2018, 2019, and 2020 valuations. The discount rate in this scenario was determined to be 22.4% based on Company’s WACC. Adjustments were made to the enterprise value for the Company’s cash and debt as of the valuation date to determine the equity value in this scenario. The OPM was used to allocate the equity value to our common stock. The equity volatility rate was determined to be 70.0% based on the volatility rate of certain comparable public companies. DLOMs of (i) 10.0% in the IPO scenario and (ii) 30.0% in the remaining private scenario were applied to the common stock. Following the closing of the initial public offering, the fair value of the Company’s common stock was determined based on the closing price of its common stock on the Nasdaq Capital Market.
Foreign currency translation and other comprehensive income	Foreign currency translation and other comprehensive income The functional currency of Tenon Technology AG is the Swiss franc. Accordingly, TTAG’s assets and liabilities are translated from their respective functional currency into U.S. Dollars at period-end rates, and TTAG’s revenue and expenses are translated at the weighted-average exchange rate for the period. Adjustments resulting from this translation process are classified as other comprehensive income or loss and shown as a separate component of equity. When intercompany foreign currency transactions between entities included in the consolidated financial statements are of a long-term investment nature (i.e., those for which settlement is not planned or anticipated in the foreseeable future) foreign currency translation adjustments resulting from those transactions are included in stockholders’ equity (deficit) as accumulated other comprehensive loss or income. When intercompany transactions are deemed to be of a short-term nature, translation adjustments are required to be included in the consolidated statements of operations.
Net loss per share	Net loss per share Basic net loss per share is based upon the weighted-average number of common shares outstanding. Diluted net loss per share is based on the assumption that all potential common stock equivalents (convertible preferred stock, stock options, and warrants) are converted or exercised. The calculation of diluted net loss per share excludes potential common stock equivalents if the effect is anti-dilutive. For the periods presented, the Company’s weighted-average common shares outstanding for basic and diluted are the same because the effect of the potential common stock equivalents is anti-dilutive. The Company had the following dilutive common stock equivalents as of December 31, 2023 and 2022 which were excluded from the calculation because their effect was anti-dilutive. December 31, December 31, Outstanding restricted stock units 76,916 131,858 Outstanding stock options 102,089 89,889 Outstanding warrants 1,927,600 9,600 Total 2,106,605 231,347
Adoption of New Accounting Pronouncements	Adoption of New Accounting Pronouncements In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update 2016-13, “ Financial Instruments-Credit Losses Measurement of Credit Losses on Financial Instruments

Summary of Significant Accoun_2

Summary of Significant Accounting Principles (Tables)	12 Months Ended
	Dec. 31, 2023
Summary of Significant Accounting Principles [Abstract]
Schedule of Dilutive Common Stock Equivalents	The Company had the following dilutive common stock equivalents as of December 31, 2023 and 2022 which were excluded from the calculation because their effect was anti-dilutive. December 31, December 31, Outstanding restricted stock units 76,916 131,858 Outstanding stock options 102,089 89,889 Outstanding warrants 1,927,600 9,600 Total 2,106,605 231,347

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2023
Investments [Abstract]
Schedule of Investments at Fair Value	The following table sets forth by level, within the fair value hierarchy, the Company’s investments at fair value as of December 31, 2023 and 2022: Level 2 Corporate debt securities: December 31, 2023 $ — December 31, 2022 $ 6,441
Schedule of Cost and Fair Value of Available for Sale Investments	Cost and fair value of available-for-sale investments as of December 31, 2023 and 2022 are as follows: Amortized Gross Gross Unrealized Losses Fair Corporate debt securities: December 31, 2023 $ — $ — $ — $ — December 31, 2022 $ 6,457 $ — $ (16 ) $ 6,441

Inventory, Net (Tables)

Inventory, Net (Tables)	12 Months Ended
	Dec. 31, 2023
Inventory [Abstract]
Schedule of Inventory net	Inventory, net of reserves, consisted of the following: December 31, December 31, Raw materials $ 22 $ 9 Finished goods 532 406 Inventory $ 554 $ 415

Fixed Assets, Net (Tables)

Fixed Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2023
Fixed Assets, Net [Abstract]
Schedule of Fixed Assets, Net	Fixed assets, net, consisted of the following: December 31, December 31, Construction in progress $ 602 $ 601 Catamaran tray sets 538 193 IT equipment 56 56 Leasehold improvements 15 — Lab equipment 14 14 Office furniture 9 9 Fixed assets, gross 1,234 873 Less: accumulated depreciation (273 ) (80 ) Fixed assets, net $ 961 $ 793

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Accrued Expenses [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following: December 31, December 31, Accrued compensation $ 334 $ 452 Other accrued expenses 474 265 Total accrued expenses $ 808 $ 717

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Schedule of Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases was as follows: December 31, December 31, Operating lease right-of-use asset $ 646 $ 873 Operating lease liability, current $ (256 ) $ (228 ) Operating lease liability, noncurrent (428 ) (683 ) Total operating lease liabilities $ (684 ) $ (911 )
Schedule of Future Maturities of Operating Lease Liabilities	Future maturities of operating lease liabilities as of December 31, 2023 were as follows: 2024 302 2025 310 2026 144 Total lease payments 756 Less: imputed interest (72 ) Present value of operating lease liabilities $ 684 Cash paid for operating leases for the year ended December 31, 2023 $ 293 Cash paid for operating leases for the year ended December 31, 2022 $ 284 Remaining lease term - operating leases (in years) 2.50 Average discount rate - operating leases 8.0 %

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Stockholders' Equity [Abstract]
Schedule of Grant Date Fair Value for Stock Options is Estimated Using a Black-Scholes Option Valuation Model Using the Weighted-Average Assumptions	Grant date fair value for stock options is estimated using a Black-Scholes option valuation model using the weighted-average assumptions in the table below: Years ended 2023 2022 Expected volatility 63.89 % 57.68 % Dividend yield 0 % 0 % Risk-free interest rate 4.28 % 3.34 % Expected term in years 5.85 5.85
Schedule of Share Option and Restricted Stock Unit Activity Under Its Plans	A summary of the Company’s share option and restricted stock unit activity under its plans is as follows: Options RSUs Number Weighted- Weighted- Number of Weighted Balance as of December 31, 2021 72,744 $ 53.18 7.12 — Granted 17,145 $ 22.98 131,858 $ 79.29 Balance as of December 31, 2022 89,889 $ 47.42 8.10 131,858 $ 79.29 Granted 15,050 $ 12.91 7,500 $ 2.91 Released — — (61,200 ) $ 82.04 Canceled (2,850 ) $ 39.87 (1,242 ) $ 88.60 Balance as of December 31, 2023 102,089 $ 42.54 7.41 76,916 $ 69.50 Exercisable at December 31, 2023 70,634 $ 48.66 6.86
Schedule of Stock-Based Compensation Expense Recognized	The following table sets forth stock-based compensation expense recognized for the years ended December 31, 2023 and 2022: Years ended 2023 2022 Research and development $ 1,504 $ 995 Sales and marketing 217 117 General, and administrative 2,424 1,785 Total stock-based compensation expense $ 4,145 $ 2,897

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies [Abstract]
Schedule of Reconciliation of the Liability	A reconciliation of the liability under clause (b) and clause (c) for the year ended December 31, 2023 is as follows: 2023 Balance at January 1, 2023 $ 2,560 Amounts paid during 2023 (592 ) Accretion 409 Balance at December 31, 2023 $ 2,377

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
Schedule of Loss Before Income Taxes	The components of loss before income taxes are as follows: Years ended 2023 2022 United States $ (15,570 ) $ (18,886 ) International (11 ) (30 ) Loss before income taxes $ (15,581 ) $ (18,916 )
Schedule of Current Income Tax Expenses	The components of current income tax expense are as follows: Years ended 2023 2022 Federal $ — $ — State — 1 Foreign — — Total income tax expense $ — $ 1
Schedule of Provision for Income Taxes	A reconciliation of the expected tax computed at the U.S. statutory federal income tax rate to the total provision for income taxes for the years ended December 31, 2023 and 2022 is as follows: Years ended 2023 2022 Statutory rate (21 )% (21 )% State taxes, net of federal benefit (7 )% (7 )% Non-deductible differences 3 % 1 % Change in valuation allowance 25 % 27 % Provision for taxes — —
Schedule of Deferred Tax Assets	Significant components of the Company’s net deferred tax assets at December 31, 2023 and 2022 are as follows: Years ended 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 9,504 $ 7,001 Credit carryforwards 220 109 Fixed assets 52 — Accruals and reserves 111 126 Stock-based compensation 1,802 843 Intangibles 220 244 Operating lease liability 188 254 Capitalized research and development 514 274 Total deferred tax assets 12,611 8,851 Valuation allowance (12,433 ) (8,564 ) Net deferred tax assets 178 287 Deferred tax liabilities: Fixed assets — (44 ) Operating lease right of use (178 ) (243 ) Total deferred tax liabilities (178 ) (287 ) Net deferred tax assets $ — —
Schedule of Recognized Tax Benefits	The following shows the changes in the gross amount of recognized tax benefits: Years ended 2023 2022 Unrecognized tax benefits, beginning of year $ 38 $ — Increases related to prior year tax positions 5 12 Decreases related to prior year tax positions — — Increases related to current year tax positions 36 26 Unrecognized tax benefits, end of year $ 79 $ 38

Summary of Significant Accoun_3

Summary of Significant Accounting Principles (Details) - USD ($) $ in Thousands		1 Months Ended			12 Months Ended
	Apr. 06, 2022	Oct. 28, 2021	Aug. 31, 2021	May 21, 2021	Dec. 31, 2023	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2022
Summary of Significant Accounting Principles [Line Items]
Reverse stock split shares (in Shares)	1
Original maturities					90 days
Allowance for expected credit losses (in Dollars)					$ 0				$ 0
Operating lease term					12 years
Percentage of weightage given to market approach			100%	100%
Discount rate percentage		27.20%	32%	22.40%
Percentage of adjustments of risk reduction		5%	5%	2%
Percentage of weightage in discounted cash flow						100%	100%	100%
IPO [Member]
Summary of Significant Accounting Principles [Line Items]
Discount rate percentage					22.40%
Volatility rate					70%
Percentage of discount for lack of marketability in initial public offering					10%
Percentage of remaining discount for lack of marketability in private placement					30%

Summary of Significant Accoun_4

Summary of Significant Accounting Principles (Details) - Schedule of Dilutive Common Stock Equivalents - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Dilutive Common Stock Equivalents [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share	2,106,605	231,347
Outstanding restricted stock units [Member]
Schedule of Dilutive Common Stock Equivalents [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share	76,916	131,858
Stock options [Member]
Schedule of Dilutive Common Stock Equivalents [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share	102,089	89,889
Outstanding warrants [Member]
Schedule of Dilutive Common Stock Equivalents [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share	1,927,600	9,600

Investments (Details)

Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Investments [Line Items]
Net gain on investments	$ 167	$ 180
Accrued interest	$ 8	$ 13

Investments (Details) - Schedul

Investments (Details) - Schedule of Investments at Fair Value - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Level 2 [Member] | Corporate Debt Securities [Member]
Corporate debt securities:
Corporate debt securities amount		$ 6,441

Investments (Details) - Sched_2

Investments (Details) - Schedule of Cost and Fair Value of Available for Sale Investments - Corporate Debt Securities [Member] - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Cost and Fair Value of Available for Sale Investments [Line Items]
Amortized Cost		$ 6,457
Gross Unrealized Gains
Gross Unrealized Losses		(16)
Fair Value		$ 6,441

Inventory, Net (Details) - Sche

Inventory, Net (Details) - Schedule of Inventory net - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Inventory [Abstract]
Raw materials	$ 22	$ 9
Finished goods	532	406
Inventory	$ 554	$ 415

Fixed Assets, Net (Details)

Fixed Assets, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Fixed Assets, net [Line Items]
Depreciation expense	$ 193	$ 78

Fixed Assets, Net (Details) - S

Fixed Assets, Net (Details) - Schedule of Fixed Assets, Net - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Fixed Assets, Net [Line Items]
Fixed assets, gross	$ 1,234	$ 873
Less: accumulated depreciation	(273)	(80)
Fixed assets, net	961	793
Construction in progress [Member]
Schedule of Fixed Assets, Net [Line Items]
Fixed assets, gross	602	601
Catamaran tray sets [Member]
Schedule of Fixed Assets, Net [Line Items]
Fixed assets, gross	538	193
IT equipment [Member]
Schedule of Fixed Assets, Net [Line Items]
Fixed assets, gross	56	56
Leasehold improvements [Member]
Schedule of Fixed Assets, Net [Line Items]
Fixed assets, gross	15
Lab equipment [Member]
Schedule of Fixed Assets, Net [Line Items]
Fixed assets, gross	14	14
Office furniture [Member]
Schedule of Fixed Assets, Net [Line Items]
Fixed assets, gross	$ 9	$ 9

Accrued Expenses (Details) - Sc

Accrued Expenses (Details) - Schedule of Accrued Expenses - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Accrued Expenses [Abstract]
Accrued compensation	$ 334	$ 452
Other accrued expenses	474	265
Total accrued expenses	$ 808	$ 717

Debt (Details)

Debt (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Feb. 20, 2024	Nov. 30, 2023	Jul. 16, 2023	Jun. 30, 2023	Apr. 30, 2022
Debt [Line Items]
Common stock at per share (in Dollars per share)				$ 3.146	$ 5.6
Term of warrants expire	5 years
Subsequent Event [Member]
Debt [Line Items]
Common stock at per share (in Dollars per share)		$ 1.2705
Subsequent Event [Member] | Series A Preferred Stock [Member]
Debt [Line Items]
Purchase of warrant		157,094
Preferred Stock of shares		84,729
Warrant [Member]
Debt [Line Items]
Purchase of warrant			45,000
Common stock at per share (in Dollars per share)			$ 1.94	$ 2.8		$ 50
Convertible Note Payable [Member]
Debt [Line Items]
Debt instrument principal amount (in Dollars)			$ 1,250,000
Common stock at per share (in Dollars per share)			$ 1,940
Convertible Notes [Member]
Debt [Line Items]
Interest rate	10%
Default interest rate	12%
Maturity date	Nov. 21, 2024
Convertible Notes [Member] | Subsequent Event [Member]
Debt [Line Items]
Common stock at per share (in Dollars per share)		$ 1,270.5000
Preferred Stock of shares		84,729
Convertible Notes [Member] | Warrant [Member] | Subsequent Event [Member]
Debt [Line Items]
Purchase of warrant		157,094
Convertible Debt [Member] | Series A Preferred Stock [Member]
Debt [Line Items]
Stated value (in Dollars)	$ 3,750,000

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Leases [Line Items]
Operating lease costs	$ 292	$ 292

Leases (Details) - Schedule of

Leases (Details) - Schedule of Supplemental Balance Sheet Information Related to Leases - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Supplemental Balance Sheet Information Related to Leases [Abstract]
Operating lease right-of-use asset	$ 646	$ 873
Operating lease liability, current	(256)	(228)
Operating lease liability, noncurrent	(428)	(683)
Total operating lease liabilities	$ (684)	$ (911)

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Future Maturities of Operating Lease Liabilities - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Future Maturities of Operating Lease Liabilities [Abstract]
2024	$ 302
2025	310
2026	144
Total lease payments	756
Less: imputed interest	(72)
Present value of operating lease liabilities	684	$ 911
Cash paid for operating leases	$ 293	$ 284
Remaining lease term - operating leases (in years)	2 years 6 months
Average discount rate - operating leases	8%

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)

12 Months Ended

Nov. 30, 2023

Jul. 24, 2023

Jul. 14, 2023

Jun. 30, 2023

Jun. 16, 2023

May 04, 2023

Apr. 30, 2022

Apr. 29, 2022

Apr. 26, 2022

Feb. 02, 2022

Jan. 10, 2022

May 31, 2021

Dec. 31, 2023

Dec. 31, 2022

Jul. 16, 2023

Feb. 18, 2014

Stockholders’ Equity [Line Items]

Common stock shares authorized (in Shares)

130,000,000

130,000,000

130,000,000

Preferred stock shares authorized (in Shares)

20,000,000

Par value

$ 0.001

Common stock par value

$ 0.001

$ 0.001

Exercise price

$ 5.6

$ 3.146

Equity ownership percentage

3%

Registered offering units shares (in Shares)

1,000,000

Proceeds net of issuance costs (in Dollars)

$ 4,808

Warrant expiration term

5 years

Aggregate gross sales price (in Dollars)

$ 5,500,000

Percentage of gross proceeds

3%

Aggregate net proceeds (in Dollars)

$ 495

Shares of common stock (in Shares)

2,600,311

1,123,680

Conversion rate description

(i) up to 12,500 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least $15.00 per share and (ii) up to 15,000 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least $25.00 per share

Purchase exceed amount (in Dollars)

$ 500,000

Purchase of shares (in Shares)

100,000

Percentage of outstanding shares

4.99%

Common stock vote

one vote

Expiration date

5 years

Weighted-average grant-date fair value of options granted

$ 7.63

$ 12.9

Aggregate intrinsic value of outstanding options (in Dollars)

$ 0

Compensation cost unvested options (in Dollars)

$ 414

Expected term unvested options

11 months 26 days

Compensation cost restricted stock units (in Dollars)

$ 4,773

Expected term restricted stock units

1 year 4 months 24 days

Issued offering warrants (in Shares)

2,000,000

Fair value of warrant grant date

$ 3,164

Fair value of per warrant grant date

1.58

Fair value price

$ 3

Daily return rate

5.18%

Short-term annual volatility

100%

Standard deviation

6.30%

Common Stock [Member]

Stockholders’ Equity [Line Items]

Issuance of common stock (in Shares)

232,100

Issued shares common stock (in Shares)

98,909

39,809

Offering Warrants [Member]

Stockholders’ Equity [Line Items]

Exercise price

$ 5.6

Warrant [Member]

Stockholders’ Equity [Line Items]

Purchase of warrant shares (in Shares)

9,600

Exercise price

$ 1.94

$ 50

$ 2.8

Expiration date

5 years

Weighted-average grant-date fair value of options granted

$ 1.29

$ 27.5

Expected term

5 years

4 years 10 months 24 days

5 years

Expected volatility

68.89%

100%

62.55%

Dividend yield

0%

0%

Risk-free interest rate

4.41%

3.99%

2.92%

Issued offering warrants (in Shares)

45,000

Fair value of warrant grant date

$ 3.146

Long-term annual volatility

60%

Warrant [Member] | Additional Paid-in Capital [Member]

Stockholders’ Equity [Line Items]

Issuance cost (in Dollars)

$ 58

$ 264,000

IPO [Member]

Stockholders’ Equity [Line Items]

Issuance of common stock (in Shares)

320,000

Common stock par value

$ 0.001

Price per share

$ 50

$ 50

Net proceeds from issuance of initial public offering (in Dollars)

$ 13,800,000

Issued shares common stock (in Shares)

8,574

Expected volatility

70%

IPO [Member] | Warrant [Member]

Stockholders’ Equity [Line Items]

Issuance cost (in Dollars)

$ 0

Underwriting Agreement [Member]

Stockholders’ Equity [Line Items]

Purchase of warrant shares (in Shares)

9,600

Exercise price

$ 50

Amended and Restated Exclusive Sales Representative Agreement [Member]

Stockholders’ Equity [Line Items]

Issuance of common stock (in Shares)

31,235

Equity ownership percentage

3%

2022 Plan [Member] | Stock options [Member]

Stockholders’ Equity [Line Items]

Expiration date

10 years

2022 Plan [Member]

Stockholders’ Equity [Line Items]

Issuance of common stock (in Shares)

37,486

Percentage of outstanding shares

4%

Shares sold (in Shares)

110,000

160,000

Minimum [Member] | 2022 Plan [Member]

Stockholders’ Equity [Line Items]

Expiration date

2 years

Maximum [Member] | 2022 Plan [Member]

Stockholders’ Equity [Line Items]

Expiration date

4 years

Convertible Note Payable [Member]

Stockholders’ Equity [Line Items]

Exercise price

$ 1,940

Conversion shares (in Shares)

395,542

Conversion of Series A and Series B Preferred Stock to Common Stock [Member]

Stockholders’ Equity [Line Items]

Conversion shares (in Shares)

269,334

Equity Distribution Agreement [Member]

Stockholders’ Equity [Line Items]

Weighted average price

$ 2.27

Series A Preferred Stock [Member]

Stockholders’ Equity [Line Items]

Par value

$ 15.125

Preferred stock, designated shares (in Shares)

4,500,000

Series B Preferred Stock [Member]

Stockholders’ Equity [Line Items]

Preferred stock, designated shares (in Shares)

491,222

Equity Line of Credit [Member]

Stockholders’ Equity [Line Items]

Shares of common stock (in Shares)

10,000

Lincoln Park Capital Fund, LLC [Member]

Stockholders’ Equity [Line Items]

Line of credit (in Dollars)

$ 10,000,000

$ 10,000,000

Closing price of common stock

$ 1.5

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of Grant Date Fair Value for Stock Options is Estimated Using a Black-Scholes Option Valuation Model Using the Weighted-Average Assumptions - Black Scholes Option [Member]	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Stockholders' Equity (Details) - Schedule of Grant Date Fair Value for Stock Options is Estimated Using a Black-Scholes Option Valuation Model Using the Weighted-Average Assumptions [Line Items]
Expected volatility	63.89%	57.68%
Dividend yield	0%	0%
Risk-free interest rate	4.28%	3.34%
Expected term in years	5 years 10 months 6 days	5 years 10 months 6 days

Stockholders' Equity (Details_2

Stockholders' Equity (Details) - Schedule of Share Option and Restricted Stock Unit Activity Under Its Plans - $ / shares		12 Months Ended
	Dec. 31, 2021	Dec. 31, 2023	Dec. 31, 2022
Stock Options [Member]
Schedule of Stock Option and Restricted Stock Unit Activity under its Plans [Line Items]
Number of Options, Granted		15,050	17,145
Weighted- Average Exercise Price per Share, Granted (in Dollars per share)		$ 12.91	$ 22.98
Number of Options, Released
Weighted- Average Exercise Price per Share, Released (in Dollars per share)
Number of Options, Canceled		(2,850)
Weighted- Average Exercise Price per Share, Canceled (in Dollars per share)		$ 39.87
Number of Options, Exercisable at December 31, 2023		70,634
Weighted- Average Exercise Price per Share, Exercisable at December 31, 2023 (in Dollars per share)		$ 48.66
Weighted- Average Remaining Contractual Term, Exercisable at December 31, 2023		6 years 10 months 9 days
Number of Options, ending balance	72,744	102,089	89,889
Weighted- Average Exercise Price per Share, ending balance (in Dollars per share)	$ 53.18	$ 42.54	$ 47.42
Weighted- Average Remaining Contractual Term, ending balance	7 years 1 month 13 days	7 years 4 months 28 days	8 years 1 month 6 days
Restricted Stock Units [Member]
Schedule of Stock Option and Restricted Stock Unit Activity under its Plans [Line Items]
Number of RSUs, Granted		7,500	131,858
Weighted Average Grant Date Fair Value per Share, Granted (in Dollars per share)		$ 2.91	$ 79.29
Number of RSUs, Released		(61,200)
Weighted Average Grant Date Fair Value per Share, Released (in Dollars per share)		$ 82.04
Number of RSUs, Canceled		(1,242)
Weighted Average Grant Date Fair Value per Share, Canceled (in Dollars per share)		$ 88.6
Number of RSUs, ending balance		76,916	131,858
Weighted Average Grant Date Fair Value per Share, ending balance (in Dollars per share)		$ 69.5	$ 79.29

Stockholders' Equity (Details_3

Stockholders' Equity (Details) - Schedule of Stock-Based Compensation Expense Recognized - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Stock-Based Compensation Expense Recognized [Line Items]
Total stock-based compensation expense	$ 4,145	$ 2,897
Research and development [Member]
Schedule of Stock-Based Compensation Expense Recognized [Line Items]
Total stock-based compensation expense	1,504	995
Sales and marketing [Member]
Schedule of Stock-Based Compensation Expense Recognized [Line Items]
Total stock-based compensation expense	217	117
General, and administrative [Member]
Schedule of Stock-Based Compensation Expense Recognized [Line Items]
Total stock-based compensation expense	$ 2,424	$ 1,785

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	6 Months Ended	12 Months Ended
	Oct. 06, 2022	Apr. 30, 2020	Jun. 30, 2023	Dec. 31, 2023	Apr. 30, 2022	Oct. 31, 2021
Sales Representative Agreement [Member]
Commitments and Contingencies [Line Items]
Agreement term		5 years
Agreement additional extension term				5 years
Cash paid				$ 500
Issued shares (in Shares)				53,757	31,235	4,445
Sales and marketing expense				$ 880
Fair value						$ 333
Bonus paid				$ 6,000
Amended and Restated Exclusive Sales Representative Agreement [Member]
Commitments and Contingencies [Line Items]
Equity ownrship percent				3%
Termination Agreement [Member]
Commitments and Contingencies [Line Items]
Cash paid	$ 1,000
Sales and marketing expense				$ 2,611
Payment amount per month	$ 85
Sales percentage	10%
Net sales amount	$ 3,600
Amount paid	$ 3,600
Payment to company			$ 85	$ 1,000
Estimated discount rate				15.40%
Ultimately expects to expense				$ 3,600
Termination Agreement [Member] | UNITED STATES
Commitments and Contingencies [Line Items]
Net sales percentage	20%
Consulting Agreement [Member]
Commitments and Contingencies [Line Items]
Consulting fee				$ 700
Additional compensation payable per quarter (in Dollars per share)				$ 62.5
Fair Value, Inputs, Level 3 [Member] | Termination Agreement [Member]
Commitments and Contingencies [Line Items]
Growth rates of fair value of liability				25%
Dissolution rate of fair value of liability				10%

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of Reconciliation of the Liability $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Schedule of Reconciliation of the Liability [Abstract]
Balance at January 1, 2023	$ 2,560
Amounts paid during 2023	(592)
Accretion	409
Balance at December 31, 2023	$ 2,377

Concentrations of Risk (Details

Concentrations of Risk (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Swiss francs [Member] | Net Assets, Geographic Area [Member]
Concentrations of Risk [Line Items]
Net assets	$ 741	$ 8

Income Taxes (Details)

Income Taxes (Details)	12 Months Ended
	Dec. 31, 2023 USD ($)
Income Taxes [Line Items]
Net operating loss carryforwards for federal income tax	$ 33,866
Carryforwards under tax cuts	33,644
Prior federal net operating loss	222
operating loss carryforwards for state	32,147
Foreign net operating loss carryforwards	1,378
Credit carryforwards	$ 214
Federal tax credits expire	2041 years
California income tax
Income Taxes [Line Items]
Credit carryforwards	$ 101

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of Loss Before Income Taxes - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Loss Before Income Taxes [Abstract]
United States	$ (15,570)	$ (18,886)
International	(11)	(30)
Loss before income taxes	$ (15,581)	$ (18,916)

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of Current Income Tax Expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Current Income Tax Expenses [Abstract]
Federal
State		1
Foreign
Total income tax expense		$ 1

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of Provision for Income Taxes	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Provision for Income Taxes [Abstract]
Statutory rate	(21.00%)	(21.00%)
State taxes, net of federal benefit	(7.00%)	(7.00%)
Non-deductible differences	3%	1%
Change in valuation allowance	25%	27%
Provision for taxes

Income Taxes (Details) - Sche_4

Income Taxes (Details) - Schedule of Deferred Tax Assets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Net operating loss carryforwards	$ 9,504	$ 7,001
Credit carryforwards	220	109
Fixed assets	52
Accruals and reserves	111	126
Stock-based compensation	1,802	843
Intangibles	220	244
Operating lease liability	188	254
Capitalized research and development	514	274
Total deferred tax assets	12,611	8,851
Valuation allowance	(12,433)	(8,564)
Net deferred tax assets	178	287
Deferred tax liabilities:
Fixed assets		(44)
Operating lease right of use	(178)	(243)
Total deferred tax liabilities	(178)	(287)
Net deferred tax assets

Income Taxes (Details) - Sche_5

Income Taxes (Details) - Schedule of Recognized Tax Benefits - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Recognized Tax Benefits [Abstract]
Unrecognized tax benefits, beginning of year	$ 38
Increases related to prior year tax positions	5	12
Decreases related to prior year tax positions
Increases related to current year tax positions	36	26
Unrecognized tax benefits, end of year	$ 79	$ 38

Subsequent Events (Details)

Subsequent Events (Details) $ / shares in Units, $ in Thousands		12 Months Ended
	Feb. 20, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Apr. 29, 2024 USD ($)	Nov. 30, 2023 $ / shares shares	Jul. 16, 2023 $ / shares	Jun. 30, 2023 $ / shares	Dec. 31, 2022 USD ($) $ / shares	Apr. 30, 2022 $ / shares shares	Dec. 31, 2021 USD ($)	Feb. 18, 2014 $ / shares
Subsequent Events [Line Items]
Common stock par value (in Dollars per share)		$ 0.001					$ 0.001
Exercise price (in Dollars per share)					$ 3.146	$ 5.6
Aggregate offering price (in Dollars) | $		$ 495
Warrants exercisable and expired term	5 years
Preferred stock stated value (in Dollars per share)										$ 0.001
Price per share (in Dollars per share)		$ 1.5125
Number of trading days		10
Percentage of volume-weighted average price		250%
Percentage of conversion into common stock shares		50
Revenues (in Dollars) | $		$ 2,250
Percentage of shares issued to shareholders		50%
Liquidation preference payable on deemed liquidation		110%
Percentage of unpaid dividend		10%
Indebtedness excess cost (in Dollars) | $		$ 1,000
Shareholdrs equity amount (in Dollars) | $		$ 778					$ 6,252		$ (20,552)
Liquidation [Member]
Subsequent Events [Line Items]
Percentage of equity		50%
Common Stock [Member]
Subsequent Events [Line Items]
Aggregate offering price (in Dollars) | $		$ 1
Shareholdrs equity amount (in Dollars) | $		$ 3					$ 1
Warrant [Member]
Subsequent Events [Line Items]
Offering warrants shares (in Shares) | shares								9,600
Exercise price (in Dollars per share)				$ 1.94	$ 2.8			$ 50
Purchase of warrant (in Shares) | shares				45,000
Series A Preferred Stock [Member]
Subsequent Events [Line Items]
Preferred stock stated value (in Dollars per share)		$ 15.125
Preferred stock issued divided (in Shares) | shares		365
Price per share (in Dollars per share)		$ 1.5125
Series A Preferred Stock [Member] | Maximum [Member]
Subsequent Events [Line Items]
Percentage of vote of an individual holder.		9.99%
Series A Preferred Stock [Member] | Minimum [Member]
Subsequent Events [Line Items]
Percentage of vote of an individual holder.		4.99%
Convertible Preferred Stock [Member]
Subsequent Events [Line Items]
Percentage of conversion into common stock shares		50
Subsequent Event [Member]
Subsequent Events [Line Items]
Common stock par value (in Dollars per share)	$ 0.001
Exercise price (in Dollars per share)	$ 1.2705
Aggregate offering price (in Dollars) | $	$ 2,605,000
Subsequent Event [Member] | Common Stock [Member]
Subsequent Events [Line Items]
Price per share (in Dollars per share)	$ 1.2705
Subsequent Event [Member] | Series A Preferred Stock [Member]
Subsequent Events [Line Items]
Preferred stock shares (in Shares) | shares	84,729
Purchase of warrant (in Shares) | shares	157,094
Subsequent Event [Member] | Series A Preferred Stock [Member] | Warrant [Member]
Subsequent Events [Line Items]
Offering warrants shares (in Shares) | shares	172,239
Subsequent Event [Member] | Common Stock [Member] | Warrant [Member]
Subsequent Events [Line Items]
Offering warrants shares (in Shares) | shares	258,374
Forecast [Member]
Subsequent Events [Line Items]
Shareholdrs equity amount (in Dollars) | $			$ 2,500